How to Reconstitute BPC-157: Storage Stability After Mixing

What BPC-157 actually is, and what it is not approved for

BPC-157 is a synthetic peptide fragment modeled on a sequence identified in gastric juice. It has not completed the FDA approval process for any human indication, and it does not have an FDA drug label. Most human use occurs through research-chemical channels or compounded preparations made by a pharmacy under Section 503A or 503B of the Federal Food, Drug, and Cosmetic Act. The FDA's own guidance on compounding explains that compounded drugs are not FDA-approved and do not undergo the agency's premarket review for safety, effectiveness, or manufacturing quality (FDA, Compounding and the FDA: Questions and Answers).

That distinction matters for this page's subject. Reconstitution and storage advice below reflects general pharmaceutical-compounding principles applied to a peptide that lacks its own manufacturer stability data, not a validated, product-specific protocol. Anyone using a compounded or research-sourced BPC-157 product should ask the supplying pharmacy or manufacturer for the actual beyond-use date and storage instructions assigned to that specific lot, since practices vary and this article cannot substitute for that information.

Why lyophilized powder is used at all

Peptides are prone to hydrolysis, oxidation, and aggregation once dissolved in water. Freeze-drying (lyophilization) removes water and halts most of that chemical activity, which is why BPC-157 is shipped as a powder rather than a pre-mixed solution. Once diluent is added, degradation processes resume, which is the underlying reason reconstituted solution is treated as time-limited rather than indefinitely stable.

Which diluent should you use: bacteriostatic water or sterile water?

Bacteriostatic water for injection (BAW) contains 0.9% benzyl alcohol as a preservative; sterile water for injection (SWFI) contains none. For a multi-dose vial that will be punctured repeatedly with a needle over days or weeks, a preserved diluent is the standard choice in general injectable compounding because it limits microbial growth introduced at each puncture. This is a general pharmaceutical principle, not a BPC-157-specific finding.

If BAW is unavailable and SWFI is used instead, the vial should be treated far more conservatively: many compounding references default to single-use or a same-day discard for preservative-free preparations, because there is no antimicrobial barrier once the vial is opened.

Normal saline is not a preservative-containing diluent and is not commonly used for peptide reconstitution. Dilute acetic acid appears in older literature for certain unrelated peptides; there is no peer-reviewed evidence specific to BPC-157 supporting acetic acid as a preferred diluent, and it should not be substituted without pharmacist guidance.

Step-by-step reconstitution

1. Wash hands thoroughly before handling any vial or syringe.
2. Wipe the rubber septum of both the diluent vial and the BPC-157 vial with a fresh alcohol swab and let it air-dry for about 30 seconds.
3. Draw the intended volume of bacteriostatic water into a syringe.
4. Insert the needle at an angle so the liquid runs down the inside glass wall of the BPC-157 vial rather than striking the powder directly.
5. Depress the plunger slowly rather than injecting a fast stream.
6. Withdraw the needle, then swirl the vial gently until the powder fully dissolves. Do not shake it. Mechanical shear from shaking is a recognized cause of protein and peptide aggregation, visible as cloudiness or foaming.
7. Label the vial with the date, calculated concentration, and diluent used.
8. Refrigerate promptly.

Calculating concentration and syringe units

The volume of diluent added sets the final concentration, which then determines how many "units" to draw on an insulin syringe (where 100 units equals 1 mL).

For a 5 mg vial:

A lower concentration (1 mg/mL) produces a larger draw volume per dose, which reduces the practical impact of a small measurement error on a syringe with coarse gradations. This is a dosing-precision consideration, not a statement about the peptide's biological effect at different concentrations.

Human dosing for BPC-157 has not been established through controlled clinical trials. Figures in the 200 to 500 mcg per injection range appear in published case reports and small observational series, but these do not constitute a validated dose-response relationship, and doses above that range have essentially no controlled human data. Anyone considering use should have an individualized discussion with a prescribing clinician rather than deriving a dose from a table on this page.

How long does reconstituted solution actually stay usable?

This is the least certain part of the protocol, and it deserves a direct statement of what is and is not known.

What is established: General sterile-compounding standards (USP General Chapter <797>) assign conservative beyond-use dates to compounded sterile preparations based on preservative content, risk category, and storage temperature, and these standards are widely applied across preserved, low-risk injectable compounds (USP <797> reference summary, NCBI Bookshelf).

What is plausible but not directly proven for BPC-157: Applying that general framework, a refrigerated (2 to 8°C), benzyl-alcohol-preserved BPC-157 solution is commonly handled as usable for roughly 28 days by compounding pharmacies and research suppliers. This figure is an extrapolation from general compounding practice, not a peptide-specific stability study, and no manufacturer stability data for reconstituted BPC-157 solution is cited in the sources available for this page.

What is not established: The exact rate of BPC-157 degradation in aqueous solution over time, whether that rate differs meaningfully from other small peptides, and whether frozen pre-drawn syringes retain full activity through a freeze-thaw cycle. Freeze-thaw cycling is a general risk factor for protein and peptide degradation, but a BPC-157-specific freeze-thaw stability study was not identified for this page.

Practical implications that follow from the above:

• A vial left at room temperature for an extended period (commonly treated as more than about 4 hours in general compounding practice) is usually discarded rather than returned to the refrigerator.
• If a solution will not be used within roughly a month, drawing individual doses into capped syringes and freezing them is a common workaround, but each thawed syringe should be treated as single-use and not refrozen.
• Unreconstituted, sealed lyophilized powder frozen at -20°C is generally described by suppliers as stable for at least several months, though this claim traces back to general lyophilized-peptide handling rather than a BPC-157-specific assay published in the literature reviewed for this page.

Drawing and injecting the dose

A 29 to 31 gauge insulin syringe with a 0.3 to 1 mL barrel is standard for small-volume subcutaneous injections generally. Finer gauges reduce injection discomfort but take slightly longer to draw. After swabbing the septum, draw an equal volume of air, inject it into the inverted vial, then withdraw the solution slowly to the target unit mark, checking for and expelling air bubbles before injecting.

Common subcutaneous injection sites include the periumbilical abdomen, lateral thigh, and back of the upper arm. Rotating sites is standard practice for any repeated subcutaneous injection to reduce localized tissue changes such as lipohypertrophy, a complication well documented with other repeatedly injected subcutaneous drugs like insulin. Whether BPC-157 carries the same site-rotation risk specifically has not been studied, but there is no reason to assume it is exempt from the general principle.

Signs the solution should be discarded

• Cloudiness or turbidity
• Visible particulate matter
• Yellow, brown, or pink discoloration
• An unusual odor on opening
• Any vial left unrefrigerated for an extended period after mixing

Clear, colorless solution is the expected baseline; any deviation is a reason to discard rather than use the dose.

What is established, what is plausible, and what is not established about safety

Animal research has examined BPC-157 in models of tendon and gastrointestinal healing, and some of this research reports a favorable acute tolerability profile at the doses tested in those models. That is animal, not human, evidence, and it does not establish human safety, effective dosing, or long-term risk. BPC-157 has not completed Phase 3 human clinical trials, and there is no FDA-reviewed human safety database comparable to what exists for approved drugs. Anyone using a compounded or research-sourced peptide should understand that unexpected reactions are, by definition, less predictable than with an approved product, and should have a plan for reporting adverse effects to a treating clinician.

A clinician-discussion and monitoring framework

This checklist is intended to structure a conversation with a prescribing clinician or compounding pharmacist, not to replace one. It does not set a dose or diagnose a reaction.

Before starting

• Confirm the exact product source (compounding pharmacy under 503A/503B, or research supplier) and ask for that source's own stability and beyond-use data rather than relying on general estimates.
• Ask the prescriber to document the reason BPC-157 is being considered, since it has no FDA-approved indication, and to record this as an off-label or compounded-use decision rather than a standard prescription.
• Disclose all current medications and supplements, since no formal drug-interaction studies for BPC-157 exist and unknown interactions cannot be ruled out.
• Confirm there is a plan for who to contact (clinic line vs. urgent care vs. emergency services) if a reaction occurs after hours.

At each reconstitution or refill checkpoint

• Re-inspect the vial before each draw: clear and colorless only.
• Re-confirm concentration and syringe units in writing before drawing, especially after switching vial concentration or diluent volume.
• Log the reconstitution date and storage location; discard on schedule rather than "if it still looks fine," since visual clarity does not rule out chemical degradation.

Stop and contact a clinician if:

• Injection site develops spreading redness, warmth, worsening pain, or fever, which may indicate infection rather than an expected local reaction.
• Any systemic symptom appears after a dose (hives, swelling of the face or throat, difficulty breathing, dizziness, chest pain), these warrant urgent or emergency evaluation, not a wait-and-see approach.
• The solution has been cloudy, discolored, or stored outside the intended temperature range and was used anyway before the issue was recognized.
• Symptoms the peptide was intended to address are worsening rather than improving after a reasonable trial period defined with the prescriber.

Boundary between label-style guidance and individualized care

Everything above is general practice applied to a peptide without its own FDA label or manufacturer-tested stability data. A prescriber or pharmacist who knows the specific product, lot, patient history, and concurrent conditions can set a more precise beyond-use date, dose, and monitoring plan than any general guide. This framework is a starting point for that conversation, not a substitute for it.

Frequently asked questions

References

• U.S. Food and Drug Administration. Compounding and the FDA: Questions and Answers. https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers
• USP General Chapter <797>, Pharmaceutical Compounding, Sterile Preparations, summarized via NCBI Bookshelf. https://www.ncbi.nlm.nih.gov/books/NBK585943/

This article summarizes general compounding and injection-safety principles applied to a peptide that lacks its own FDA label or published stability data. It is pending qualified clinical review and should not be used to set an individual dose, diagnose a reaction, or replace guidance from the prescribing clinician or dispensing pharmacy.